InvestSMART

Firebrick Pharma Limited (ASX:FRE)

ALERT: Price-sensitive ASX Announcement for FRE
Current share price for FRE : $0.028 -0.035 (-55.56%)+
Announcement
Release
21 Jan 2026 8:23AM
Price at Release
$0.063
Full Release
download
Summary
Firebrick Pharma Limited has launched its Nasodine® Throat Spray in Singapore, marking its first international market entry. The throat spray, which uses a 1% povidone-iodine solution for oral use, complements the Nasodine® Nasal Spray and aims to offer a convenient solution for sore throats, often the first sign of a cold. The product is launched through Firebrick's exclusive licensing partner, Innorini Life Sciences, and will initially target hospitals and healthcare professionals before expanding to retail channels. This international expansion is part of a broader strategy to build a Nasodine product franchise across multiple markets, including planned future introductions in Fiji, the USA, and other regions where the nasal spray is approved. The product does not require local regulatory approval for sale in Singapore, unlike in Australia, and is priced competitively online.
Key Points
  • Nasodine Throat Spray launched in Singapore, first international market.
  • Product complements Nasodine Nasal Spray.
  • Exclusive licensing partner: Innorini Life Sciences.
  • Initial focus on hospitals and healthcare professionals.
  • Expansion to retail channels planned.
  • Future introductions planned in Fiji, USA, and other markets.
  • No local regulatory approval required in Singapore.
  • Priced at S$19.99, 20% lower than the nasal spray.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.